First Relapse in Myeloma: Barriers to CAR-T, Bispecifics & New Treatments | IMS 2026

Martin Kaiser, MD, of The Institute of Cancer Research and The Royal Marsden, London discusses limited access to new treatments at first relapse at IMS 2026 in Glasgow. CAR-T, bispecific antibodies and antibody-drug conjugates have shown remarkable results, but many patients cannot get them. He explains barriers such as limited access in lower-income countries, reimbursement decisions, travel distance and frequent visits. He also discusses how earlier collaboration on evidence could speed access, and why proven triplet therapies remain an option before moving to newer treatments later.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction

0:22 New treatments at first relapse

1:10 Global access to cell therapies

1:39 Barriers in public health systems

2:13 Collaborating on evidence

2:54 Practical barriers: centers, travel and visits

3:35 Good options when newer treatments aren't available

4:07 Working together for broader access